- Home
- ACEL vs GYRE Comparison
ACEL vs GYRE Comparison
Compare ACEL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACEL
- GYRE
- Stock Information
- Founded
- ACEL 2009
- GYRE 2002
- Country
- ACEL United States
- GYRE United States
- Employees
- ACEL N/A
- GYRE N/A
- Industry
- ACEL Services-Misc. Amusement & Recreation
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ACEL Consumer Discretionary
- GYRE Health Care
- Exchange
- ACEL Nasdaq
- GYRE Nasdaq
- Market Cap
- ACEL 934.8M
- GYRE 897.1M
- IPO Year
- ACEL N/A
- GYRE N/A
- Fundamental
- Price
- ACEL $11.17
- GYRE $7.90
- Analyst Decision
- ACEL Buy
- GYRE Strong Buy
- Analyst Count
- ACEL 1
- GYRE 1
- Target Price
- ACEL $16.00
- GYRE $18.00
- AVG Volume (30 Days)
- ACEL 318.5K
- GYRE 96.3K
- Earning Date
- ACEL 10-29-2025
- GYRE 11-12-2025
- Dividend Yield
- ACEL N/A
- GYRE N/A
- EPS Growth
- ACEL N/A
- GYRE N/A
- EPS
- ACEL 0.40
- GYRE 0.02
- Revenue
- ACEL $1,279,563,000.00
- GYRE $102,189,000.00
- Revenue This Year
- ACEL $9.99
- GYRE $18.39
- Revenue Next Year
- ACEL $5.17
- GYRE $48.26
- P/E Ratio
- ACEL $27.96
- GYRE $469.46
- Revenue Growth
- ACEL 7.00
- GYRE N/A
- 52 Week Low
- ACEL $9.02
- GYRE $6.11
- 52 Week High
- ACEL $13.28
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- ACEL 44.32
- GYRE 51.30
- Support Level
- ACEL $10.99
- GYRE $7.55
- Resistance Level
- ACEL $11.41
- GYRE $8.56
- Average True Range (ATR)
- ACEL 0.25
- GYRE 0.51
- MACD
- ACEL 0.00
- GYRE -0.01
- Stochastic Oscillator
- ACEL 22.42
- GYRE 57.14
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.